Colony Group’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-10,588
| Closed | -$372K | – | 820 |
|
|
2022
Q4 | $372K | Buy |
+10,588
| New | +$353K | 0.01% | 680 |
|
|
2022
Q3 | – | Sell |
-7,590
| Closed | -$413K | – | 800 |
|
|
2022
Q2 | $413K | Buy |
7,590
+3,733
| +97% | +$206K | 0.01% | 637 |
|
|
2022
Q1 | $210K | Sell |
3,857
-3,733
| -49% | -$203K | ﹤0.01% | 804 |
|
|
2021
Q4 | $418K | Buy |
+7,590
| New | +$395K | 0.01% | 625 |
|
|
2021
Q2 | – | Sell |
-4,494
| Closed | -$200K | – | 778 |
|
|
2021
Q1 | $200K | Sell |
4,494
-3,795
| -46% | -$172K | ﹤0.01% | 735 |
|
|
2020
Q4 | $381K | Buy |
8,289
+3,919
| +90% | +$180K | 0.01% | 555 |
|
|
2020
Q3 | $206K | Sell |
4,370
-372
| -8% | -$18.6K | 0.01% | 681 |
|
|
2020
Q2 | $242K | Sell |
4,742
-162
| -3% | -$8.31K | 0.01% | 601 |
|
|
2020
Q1 | $232K | Sell |
4,904
-279
| -5% | -$14.9K | 0.01% | 606 |
|
|
2019
Q4 | $304K | Sell |
5,183
-266
| -5% | -$14.8K | 0.01% | 629 |
|
|
2019
Q3 | $291K | Sell |
5,449
-1,283
| -19% | -$66K | 0.01% | 587 |
|
|
2019
Q2 | $337K | Sell |
6,732
-1,165
| -15% | -$58.5K | 0.01% | 573 |
|
|
2019
Q1 | $413K | Buy |
7,897
+3,510
| +80% | +$175K | 0.02% | 439 |
|
|
2018
Q4 | $210K | Buy |
4,387
+24
| +0.6% | +$1.18K | 0.01% | 464 |
|
|
2018
Q3 | $219K | Buy |
4,363
+122
| +3% | +$6.2K | 0.01% | 472 |
|
|
2018
Q2 | $214K | Sell |
4,241
-5
| -0.1% | -$252 | 0.01% | 467 |
|
|
2018
Q1 | $207K | Buy |
+4,246
| New | +$198K | 0.01% | 471 |
|
|
2017
Q3 | – | Sell |
-57,839
| Closed | -$3.12M | – | 455 |
|
|
2017
Q2 | $3.12M | Buy |
57,839
+3,133
| +6% | +$167K | 0.22% | 94 |
|
|
2017
Q1 | $2.88M | Buy |
+54,706
| New | +$2.78M | 0.27% | 79 |
|
|
2016
Q1 | – | Sell |
-57,998
| Closed | -$2.92M | – | 400 |
|
|
2015
Q4 | $2.92M | Sell |
57,998
-1,040
| -2% | -$53K | 0.27% | 82 |
|
|
2015
Q3 | $2.84M | Buy |
59,038
+80
| +0.1% | +$4.16K | 0.33% | 69 |
|
|
2015
Q2 | $3.07M | Buy |
58,958
+57,532
| +4,035% | +$3.24M | 0.32% | 69 |
|
|
2015
Q1 | $82K | Sell |
1,426
-60,224
| -98% | -$3.45M | 0.01% | 377 |
|
|
2014
Q4 | $3.29M | Buy |
61,650
+2,568
| +4% | +$144K | 0.34% | 70 |
|
|
2014
Q3 | $3.4M | Buy |
59,082
+57,532
| +3,712% | +$3.53M | 0.38% | 58 |
|
|
2014
Q2 | $104K | Sell |
1,550
-14,656
| -90% | -$992K | 0.01% | 266 |
|
|
2014
Q1 | $1.08M | Buy |
16,206
+84
| +0.5% | +$5.68K | 0.15% | 115 |
|
|
2013
Q4 | $1.08M | Buy |
+16,122
| New | +$1.05M | 0.15% | 115 |
|
Other funds holding GSK
JEST
Colony Group's GSK Position: Q1 2023 in Review
Colony Group sold out of GSK (GSK) in Q1 2023, closing a stake of 10,588 shares — an estimated $372K sold.
Colony Group first reported a position in GSK in Q4 2013 and held it in 28 quarters. The position peaked at $3.4M in Q3 2014. 809 funds tracked by Wall St. Rank hold GSK as of Q1 2023.
- Colony Group reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
- Colony Group sold 10,588 GSK shares in Q1 2023, an estimated $372K.
- Colony Group first reported a position in GSK in Q4 2013 and held it in 28 quarters.
- Colony Group's GSK position peaked at $3.4M in Q3 2014.
- 809 funds tracked by Wall St. Rank held GSK as of Q1 2023.
Based on Colony Group's 13F filing for Q1 2023, filed 16 May 2023.